国泰君安证券股份有限公司 关于杭州博拓生物科技股份有限公司 2023年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上 市规则（2020年12月修订）》（以下简称"《科创板上市规则》"）、《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求》、《上海证券 交易所科创板上市公司自律监管指引第1号——规范运作》等有关法律、法规的 规定，国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作 为杭州博拓生物科技股份有限公司（以下简称"博拓生物"、"上市公司"或"公 司"）持续督导工作的保荐机构，负责博拓生物上市后的持续督导工作，并出具 本持续督导跟踪报告。 （一）技术风险 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体的持 续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执行 了持续督导制度，并制定了相应的 | | | | 工作计划 | | | 根据中国证监会相关规定，在持续督导工作开始前，与上 市公司或相关当事人签署持续督导协议，明确双方在持 ...

国泰君安证券股份有限公司 关于杭州博拓生物科技股份有限公司 首次公开发行股票部分募投项目结项并将部分节余募集资金永久补 充流动资金的核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"、"保荐机构"）作为 杭州博拓生物科技股份有限公司（以下简称"博拓生物"、"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规 则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规 定，对博拓生物调技部分募投项目结项并将部分节余募集资金永久补充流动资金 事项进行了审慎核查，核查情况及核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 7 月 27 日出具的《关于同意杭州博拓生物科技股份有限公司首次公开发行股票注册 的批复》（证监许可〔2021〕2497 号），公司获准向社会公开发行人民币普通 股 2,666.6667 万股，每股发行价格为人民币 34.55 元，募集资金总额为 92,133.33 万元，扣除发行费用 9,196.41 万 ...

首次公开发行战略配售限售股上市流通的核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作 为杭州博拓生物科技股份有限公司（以下简称"博拓生物"或"公司"）首次 公开发行股票并在科创板上市的保荐机构，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上海证券交易所科创板股票上市规则（2020年 12月修订）》、《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关规定，对博拓生物首次公开发行部分限售股上市流通事项进行了 核查，具体情况如下： 国泰君安证券股份有限公司 关于杭州博拓生物科技股份有限公司 一、本次上市流通的限售股类型 中国证券监督管理委员会于2021年7月27日出具《关于同意杭州博拓生物科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2497号）， 同意公司首次公开发行股票的注册申请。首次向社会公开发行人民币普通股 （A股）26,666,667股，并于2021年9月8日在上海证券交易所科创板上市交易， 发行完成后总股本为106,666,667股，其中有限售条件流通股84,455,871股，无限 售条件流通股22,210,796股。 ...

证券代码：688767 证券简称：博拓生物 公告编号：2023-022 杭州博拓生物科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"或"博拓生物"）于 2023 年 8 月 28 日召开公司第三届董事会第九次会议、第三届监事会第七次会议，审议 通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司在保证 不影响募集资金投资项目实施、不变相改变募集资金使用用途、不影响公司正常运 营及确保募集资金安全的前提下,使用最高不超过人民币 60,000 万元的暂时闲置 募集资金进行现金管理，用于购买投资安全性高、流动性好、具有合法经营资格的 金融机构销售的满足保本要求的理财产品或存款类产品（包括但不限于协定性存款、 结构性存款、定期存款、通知存款、大额存单等）。自董事会审议通过之日起 12 个 月内有效。在前述额度及期限范围内，公司可以循环滚动使用该资金。公司董事会 授权董事长在上述额度及决议有效期内行使投资决策 ...

证券代码：688767 证券简称：博拓生物 公告编号：2023-023 杭州博拓生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要提示： 上海证券交易所上证路演中心上海证券交易所上证路演中心 投资者可于 2023 年 9 月 1 日（星期五）至 9 月 5 日（星期二）16:00 前登 录上证 路演中心 网站首页点击"提问预征集"栏目或 通过公司邮箱 ir.secretary@biotests.com.cn 进行提问，公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 杭州博拓生物科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司 2023 年半年度报告，为 便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公 司计划于 2023 年 9 月 6 日上午 10:00-11:00 举行 2023 年半年度业绩说明会， 就投资者关心的问题进 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召 开了第三届董事会第九次会议和第三届监事会第七次会议，审议通过了《关于部分 募投项目结项并将部分节余募集资金永久补充流动资金的议案》，公司首次公开发 行股票募集资金投资项目（以下简称"募投项目"）的"年产 4 亿人份医疗器（体 外诊断）产品扩建升级建设项目"与"体外诊断产品生产线智能化改造建设项目" 已达到预定可使用状态，现拟将上述两项募投项目结项，并将"体外诊断产品生产 线智能化改造建设项目"节余募集资金永久补充流动资金。公司独立董事对本次事 项发表了明确同意的独立意见，保荐机构国泰君安证券股份有限公司（以下简称"保 荐机构"）对本次事项出具了明确同意的核查意见。现将具体情况公告如下： 一、募集资金基本情况 中国证券监督管理委员会于 2021 年 7 月 27 日下发《关于同意杭州博拓生物科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2497 号），同意 公司首次公开发 ...

国泰君安证券股份有限公司 关于杭州博拓生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为杭 州博拓生物科技股份有限公司（以下简称"博拓生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券交 易所科创板上市公司自律监管指引第1号——规范运作》等法律法规和规范性文件的 要求，对博拓生物使用部分暂时闲置募集资金进行现金管理事项进行了审慎核查， 核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于2021 年7 月27 日出具的《关于同意杭州博拓生物科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2021〕2497号），公司获准向社会公开发行人民币普通股2,666.6667万 股，每股发行价格为人民币34.55元，募集资金总额为 92,133.33 万元，扣除发行费 用 9,196.41 万元（不含增值税）后，募集资金净额为 82,936.92万元。上述募集 ...

证券代码：688767 证券简称：博拓生物 公告编号：2023-018 杭州博拓生物科技股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 表决结果：同意：3 票；反对：0 票；弃权：0 票。 （三）审议通过了《关于首次公开发行股票部分募投项目结项并将部分节余 募集资金永久补充流动资金的议案》 监事会认为：公司首次公开发行股票部分募投项目"年产 4 亿人份医疗器 （体外诊断）产品扩建升级建设项目"与"体外诊断产品生产线智能化改造建设 项目"结项并将部分节余募集资金永久性补充流动资金事项符合《上海证券交易 所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》等有关法律法规、规范性文件以及公司《募集资金管理制度》的规定， 是为了满足公司战略规划及实际经营的需要，不存在损害公司及股东利益的情形。 表决结果：同意：3 票；反对：0 票；弃权：0 票。 杭州博 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,901,143,935.01, representing a 4.57% increase compared to ¥1,818,075,902.95 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥773,654,174.47, a decrease of 7.19% from ¥833,590,633.07 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥755,960,336.25, down 8.42% from ¥825,500,564.78 in the previous year[19]. - The cash flow from operating activities for 2022 was ¥703,211,818.75, a decline of 22.56% compared to ¥908,123,247.63 in 2021[19]. - The total assets at the end of 2022 were ¥2,751,217,156.02, reflecting a 13.15% increase from ¥2,431,508,922.58 at the end of 2021[19]. - The net assets attributable to shareholders increased by 21.55% to ¥2,561,259,556.96 at the end of 2022, up from ¥2,107,098,138.47 in 2021[19]. - The basic earnings per share for 2022 were ¥7.25, a decrease of 24.64% from ¥9.62 in 2021[20]. - The company reported a gross margin of 60% for the latest quarter, reflecting improved operational efficiency and cost management[68]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 25%[175]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 5.69% in 2022, up from 3.41% in 2021, indicating a focus on innovation[21]. - The total R&D investment for the year reached ¥108,208,922.33, a significant increase of 74.74% compared to ¥61,924,538.08 from the previous year[79]. - R&D expenses accounted for 5.69% of total revenue, up from 3.41%, reflecting an increase of 2.28 percentage points[79]. - The company has a strong focus on R&D, with a total of 290 applications for patents and copyrights, of which 206 have been granted[60]. - The company is investing in R&D for new technologies, with a budget allocation of $5 million for the development of next-generation diagnostic tests in 2023[67]. - The company is focusing on expanding its product offerings in the field of molecular diagnostics, targeting both human and animal health markets[87]. - The company has successfully developed five major diagnostic reagent projects, including rapid tests for reproductive health and drug abuse, achieving a leading position domestically and internationally[95]. Product Development and Innovation - The company developed 32 new diagnostic reagents and obtained CE certification, enhancing its product offerings in the market[31]. - A total of 13 new patents were granted during the reporting period, including 4 invention patents, which strengthens the company's intellectual property portfolio[32]. - The company launched a total of 87 new diagnostic products in 2022, focusing on various diseases and conditions, which indicates a strong commitment to innovation and market expansion[65]. - The company is focusing on the development of combination tests for respiratory viruses, which is expected to capture a larger market segment[72]. - The company has developed a new COVID-19 antigen product, with clinical trials partially completed and further projects in development[86]. - The company is actively pursuing EU IVDR certification for over 70 products, indicating a commitment to meeting evolving regulatory standards in the European market[10]. Market Expansion and Sales Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21]. - The company expanded its international sales channels, entering new markets such as Australia, Canada, Russia, and Mexico, while strengthening partnerships with key distributors in North America, leading to a recovery and steady growth in sales of routine products[34]. - The company aims to enhance its market presence through strategic partnerships and potential acquisitions in the diagnostics field, targeting a 10% increase in revenue from these initiatives[67]. - The company is expanding its market presence in Europe and Asia, targeting a 20% increase in market share by the end of 2023[69]. - The company is exploring potential acquisitions to enhance its capabilities in the diagnostics sector, with a focus on companies that complement its existing product lines[75]. Financial Management and Governance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors has approved the profit distribution plan, which is subject to shareholder approval[5]. - The company has not reported any instances of more than half of the directors being unable to ensure the accuracy and completeness of the annual report[7]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development[4]. - The company has not disclosed any special arrangements for corporate governance[7]. Risks and Challenges - The company has identified significant risk factors that may adversely affect its operations, which are detailed in the management discussion section[4]. - The decline in demand and pricing for COVID-19 testing products negatively impacted overall revenue and profit margins during the year[30]. - The company faces risks related to new product development and registration, which may impact its market competitiveness if not managed effectively[103]. - The demand for COVID-19 testing products has decreased significantly, posing a risk to the sustainability of the company's revenue growth[106]. - The company is at risk of losing market access if it fails to renew necessary certifications and licenses for its products[108]. Corporate Social Responsibility and Sustainability - The company is committed to sustainability initiatives, with plans to reduce its carbon footprint by 15% over the next three years[68]. - The management team emphasized the importance of sustainability in future operations, aiming to reduce carbon emissions by 20% over the next five years[175].

Financial Performance - The company's operating revenue for Q1 2023 was ¥103,685,805.87, representing a decrease of 89.81% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2023 was ¥11,899,389.65, down 97.58% year-over-year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,055,122.92, a decline of 98.13% compared to the previous year[10]. - Basic earnings per share for Q1 2023 were ¥0.11, down 97.62% from the same period last year[6]. - The company reported a net profit of CNY 1,723,502.30 in Q1 2023, down from CNY 6,684,565.40 in Q1 2022[20]. - The net profit for Q1 2023 was ¥11,502,242.39, a significant decrease from ¥493,587,345.24 in Q1 2022, reflecting a decline of approximately 97.67%[21]. - The total operating income for Q1 2023 was ¥13,671,180.79, compared to ¥581,192,726.47 in Q1 2022, indicating a decrease of about 97.65%[21]. - The total comprehensive income for Q1 2023 was ¥12,210,106.37, down from ¥493,573,794.84 in Q1 2022, marking a decline of approximately 97.53%[21]. Cash Flow - The net cash flow from operating activities was -¥20,061,528.63, reflecting a decrease of 102.88% year-over-year[10]. - The cash flow from operating activities showed a net outflow of ¥20,061,528.63 in Q1 2023, contrasting sharply with a net inflow of ¥696,516,794.88 in Q1 2022[24]. - The total cash inflow from operating activities in Q1 2023 was ¥120,899,027.45, compared to ¥1,357,734,415.90 in Q1 2022, reflecting a decrease of approximately 91.10%[23]. - The total cash outflow from operating activities in Q1 2023 was ¥140,960,556.08, down from ¥661,217,621.02 in Q1 2022, indicating a decrease of about 78.73%[24]. - The cash flow from investing activities showed a net outflow of ¥9,292,153.48 in Q1 2023, compared to a net outflow of ¥36,326,849.89 in Q1 2022[24]. - The company reported a decrease in tax payments, with ¥10,020,530.98 in Q1 2023 compared to ¥47,225,529.56 in Q1 2022, a reduction of approximately 78.77%[24]. Research and Development - The total R&D investment amounted to ¥9,880,272.83, a reduction of 49.56% compared to the previous year[6]. - The proportion of R&D investment to operating revenue increased by 7.60 percentage points to 9.53%[6]. - Research and development expenses decreased to CNY 9,880,272.83, a reduction of 49.53% compared to CNY 19,586,991.87 in the same period last year[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,729,306,540.87, a decrease of 0.80% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to CNY 2,729,306,540.87, a decrease from CNY 2,751,217,156.02 at the end of 2022[18]. - Total liabilities decreased to CNY 154,799,346.12 from CNY 188,920,067.64 at the end of 2022, reflecting a reduction of 18.06%[18]. - The company's equity attributable to shareholders increased to CNY 2,573,796,024.20 from CNY 2,561,259,556.96 at the end of 2022[18]. Market Demand - The company attributed the significant decline in revenue and profit primarily to a sharp decrease in market demand for COVID-19 testing products[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,297[13].